0000912282-25-000613.txt : 20250606 0000912282-25-000613.hdr.sgml : 20250606 20250606170725 ACCESSION NUMBER: 0000912282-25-000613 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250604 FILED AS OF DATE: 20250606 DATE AS OF CHANGE: 20250606 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bray June CENTRAL INDEX KEY: 0001845487 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38890 FILM NUMBER: 251031972 MAIL ADDRESS: STREET 1: C/O BIOXCEL THERAPEUTICS, INC. STREET 2: 555 LONG WHARF DRIVE CITY: NEW HAVEN STATE: CT ZIP: 06511 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Quince Therapeutics, Inc. CENTRAL INDEX KEY: 0001662774 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 901024039 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 611 GATEWAY BLVD., SUITE 273 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 415-910-5717 MAIL ADDRESS: STREET 1: 611 GATEWAY BLVD., SUITE 273 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Cortexyme, Inc. DATE OF NAME CHANGE: 20160104 4 1 form4.xml X0508 4 2025-06-04 0001662774 Quince Therapeutics, Inc. QNCX 0001845487 Bray June C/O QUINCE THERAPEUTICS, INC. 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080 true false Director Stock Option (Right to Buy) 1.09 2025-06-04 4 A 0 27000 0 A 2035-06-04 Common Stock 27000 27000 D The shares subject to the option shall vest 100% on the one-year anniversary of the grant date. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy. /s/ Brendan Hannah as attorney-in-fact for June Bray 2025-06-06